MERCK KGAA

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1668-01-01

Employees: 62.9K

Market Cap: $84.2B

Website: http://www.merckgroup.com/de

Clinical Trials

Study of AS902330 (rhFGF-18) Administered Intra-articularly in Patients With Knee Primary Osteoarthritis Who Are Candidates for Total Knee Replacement

Phase 1

Completed

Conditions: Knee Osteoarthritis

Interventions: Drug: AS902330
Drug: Placebo

First Posted Date: 2009-06-02

Last Posted Date: 2014-08-05

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 73

Registration Number: NCT00911469

Locations: 🇸🇪
Hässleholms Sjukhus, Hässleholm, Sweden
🇸🇪
Malmö University Hospital, Malmö, Sweden
🇬🇧
Cambridge University Hospitals, Cambridge, United Kingdom

and more 16 locations

EMD 521873 Plus Radiotherapy in Non Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Lung Cancer
Non Small Cell Lung Cancer

Interventions: Biological: EMD 521873

First Posted Date: 2009-04-13

Last Posted Date: 2014-06-23

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 15

Registration Number: NCT00879866

Locations: 🇳🇱
Department of Pulmonology, Academic Hosptial Maastricht, Masstricht, Netherlands
🇳🇱
Department of Thoracic Oncology, Netherlands Cancer Instiute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
🇳🇱
Department of Medical Oncology (452), Radboud UMC Nijmegen, Nijmegen, Netherlands

Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Phase 2

Completed

Conditions: Carcinoma of the Head and Neck

Interventions: Drug: Cetuximab

First Posted Date: 2009-03-19

Last Posted Date: 2014-03-12

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 27

Registration Number: NCT00865098

Locations: 🇯🇵
Research Site, Tokyo, Japan

EMD 525797 in Colorectal and Ovarian Cancer Patients With Liver Metastases

Phase 1

Completed

Conditions: Colorectal and Ovarian Cancer Patients With Liver Metastases

Interventions: Biological: EMD 525797

First Posted Date: 2009-02-20

Last Posted Date: 2015-12-14

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 41

Registration Number: NCT00848510

Locations: 🇬🇧
Christie Hospital, Manchester, United Kingdom

Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Cilengitide
Drug: Cetuximab
Drug: Cisplatin
Drug: Chemotherapy
Drug: Vinorelbine
Drug: Gemcitabine

First Posted Date: 2009-02-12

Last Posted Date: 2017-01-13

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 232

Registration Number: NCT00842712

Locations: 🇪🇸
Research Site, Barcelona, Spain

CONSORT Randomized Controlled Trial in Assisted Reproductive Technology

Phase 4

Completed

Conditions: Infertility

Interventions: Drug: GONAL f® prefilled pen

First Posted Date: 2009-01-26

Last Posted Date: 2014-02-13

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 200

Registration Number: NCT00829244

Locations: 🇨🇭
Research Site, Geneva, Switzerland

Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC)

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer (NSCLC)

Interventions: Drug: Cetuximab 500 mg/m^2
Drug: Cetuximab 250 mg/m^2
Drug: Cetuximab plus Platinum-based Doublet Chemotherapy

First Posted Date: 2009-01-12

Last Posted Date: 2014-05-05

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 583

Registration Number: NCT00820755

Locations: 🇩🇪
Central Contact, Darmstadt, Germany

Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)

Phase 3

Completed

Conditions: Clinically Isolated Syndrome
Multiple Sclerosis

Interventions: Drug: RNF
Drug: Placebo

First Posted Date: 2008-12-23

Last Posted Date: 2017-03-08

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 402

Registration Number: NCT00813709

Locations: 🇪🇸
Research Site, Seville, Spain
🇷🇸
Reserch Site, Belgrade, Serbia

Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study)

Phase 1

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Cetuximab
Drug: FOLFIRI
Drug: FOLFOX

First Posted Date: 2008-10-23

Last Posted Date: 2015-05-14

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 289

Registration Number: NCT00778830

Locations: 🇸🇬
Research Site, Singapore, Singapore

TRUST Study: Raptiva ® in Hand & Foot Psoriasis

Phase 4

Terminated

Conditions: Chronic Plaque Psoriasis

Interventions: Drug: Placebo
Drug: Efalizumab - anti CD11a recombinant human monoclonal antibody

First Posted Date: 2008-08-22

Last Posted Date: 2014-02-27

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 76

Registration Number: NCT00739882

Locations: 🇦🇹
University of Vienna Medical School, Vienna, Austria

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy